578P Interim analysis of a phase II study of SHR-1210 combined with neoadjuvant chemoradiation in patients with locally advanced proximal stomach adenocarcinoma (Neo-PLANET)

Wang, X.; Wang, Y.; Tang, Z-Q.; Yu, Yiyi; Cui, Yu-Hong; Tang, Cong; Sun, Jian; Zhang, Q.; Ji, Yuan; Ma, Guansheng; Shen, Zhijian; Liu, F.; Shen, Kui; Liu, T.; Sun, Yun

doi:10.1016/j.annonc.2020.08.692

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients were required to receive four cycles of XELOX adjuvant chemotherapy within 4–6 weeks postoperatively. Results indicated that camrelizumab combined with radiation and chemotherapy was an effective treatment for patients with locally advanced GC, ORR was 93.3%, the pathological complete response (pCR) rate was 33.3%, the primary endpoint of the phase I trial, and the phase II trial was ongoing ( 70 , 71 ). Neoadjuvant concurrent chemoradiotherapy followed by surgery in patients with locally advanced esophageal, or GEJA, who received durvalumab showed an excellent survival benefit with 2-year recurrence-free survival and OS of 55.5% and 67.4%, respectively ( 72 ).…”

Section: Icis Combined With Other Treatments Of Advanced Gcmentioning

confidence: 99%

Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review

Shen

Wang

2022

Front. Oncol.

View full text Add to dashboard Cite

Most patients with advanced gastric cancer were treated with palliative therapy, which had a poor curative effect and a short survival time. In recent years, the clinical research of immune checkpoint inhibitors in advanced gastric cancer has made a breakthrough and has become an important treatment for advanced gastric cancer. The modes of immune checkpoint inhibitors in the treatment of advanced gastric cancer include single drug, combined chemotherapy, radiotherapy, and multiple immune drug combination therapy, among which combination therapy shows better clinical efficacy, and a large number of trials are currently exploring more effective combination therapy programs. In this paper, the new clinical research progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer is reviewed, with an emphasis on combination therapy.

show abstract

Section: Icis Combined With Other Treatments Of Advanced Gcmentioning

confidence: 99%